


IN THE CLAIMS

1 1. (Original) Use of compounds of the general Formula



2

3 (wherein

4 R³ stands for hydrogen or hydroxy;
5 R¹ stands for hydrogen or alkyl; and
6 R² stands for alkyl)7 and pharmaceutically acceptable acid addition salts for the
8 preparation of pharmaceutical compositions having neuroprotective
9 effect.1 2. (Original) Use according to Claim 1 for the
2 preparation of pharmaceutical compositions suitable for the
3 reduction of the consequences of acute ischemic or traumatic brain
4 and spinal damages, especially the various types of stroke or
5 cerebral vasospasm, severe brain vessel occlusion, neuronal loss

6 and its functional consequences in the case of head and spinal
7 injuries caused by accidents.


1 3. (Original) Use according to Claim 1 for the
2 preparation of pharmaceutical compositions having chronical
3 neurodegenerative effect.

1 4. (Original) Use according to Claim 3 for the
2 preparation of pharmaceutical composition suitable for the
3 treatment of motoneuron disease (ALS), sclerosis multiplex or
4 Creutzfeld- Jakob disease.


1 5. (Original) Use according to ~~any of Claims 1-4~~ Claim 1
2 wherein (1R,2S,4R)-(-)-2-(2-dimethylaminoethoxy)-2-phenyl-1,7,7-
3 trirnethyl-bicyclo[2.2.1]heptane (deramciclane) or a
4 pharmaceutically acceptable acid addition salt is used as compound
5 of the general Formula I.

1 6. (Original) Use according to Claim 5 wherein
2 (1R,2S,4R)-(-)-2-(2- dimethylaminoethoxy)-2-phenyl-1,7,7-trimethyl-
3 bicyclo[2.2.1]heptane-fumarate (deramciclane-fumarate) is used as
4 compound of the general Formula I.

1 7. (Original) Use according to Claim 1 wherein
2 (1R,2S,4R)-(-)-2-(2-dimethylaminoethoxy)-2-phenyl-1,7,7-trimethylbi
3 cyclo[2.2.1]heptane of the Formula



4 or a pharmaceutically acceptable acid addition salt containing not
5 more than 0.2 % of (1R,3S,4R)-342-(N,Ndimethylaminoethyl)]-
6 1,7,7-timethyl-bicyclo[2.2.1]heptane-2- one of the Formula



7 or a pharmaceutically acceptable acid addition salt thereof is used
8 as compound of the general Formula I.

1 8. (Original) Use according to Claim 7 wherein
2 (1R,2S,4R)-(+2-(2-dimethylaminoethoxy)-2-phenyl-1,7,7-trimethylbicyc
3 clo[2.2.1]heptane-fumarate containing not more than 0.2 % of
4 (1R,3S,4R)-342-(N,N-dimethylaminoethyl)-1,7,7-trimethylbicyclo-
5 [2.2.1]heptane-2-one-fumarate is used as compound of the general
6 Formula I.

1 9. (Currently amended) Use according to claim 1 any of
2 claims 1-4 wherein
3 (1R,2S,4R)-(-)-2-(2-methylaminoethoxy)-2-phenyl-1,7,7-
4 trimethyl-bicyclo[2.2.1]heptane;
5 (1R,2S,7R)-2-phenyl-2-(2-methylaminoethoxy)-7-
6 hydroxymethyl-1,7-dimethyl-bicyclo[2.2.1]heptane; or
7 (1R,2S,7R)-2-phenyl-2-(2-ethylaminoethoxy)-7-
8 hydroxymethyl-1,7-dimethyl-bicyclo[2.2.1]heptane
9 or a pharmaceutically acceptable acid addition salt thereof is used
10 as compound of the general Formula I.

1 10. (Currently amended) Neuroprotective pharmaceutical
2 composition comprising as active ingredient a compound of the
3 general Formula I as defined in claim 1 (wherein R¹, R² and R³ are
4 as stated in Claim 1) or a pharmaceutically acceptable acid
5 addition salt thereof in admixture with inert pharmaceutically
6 acceptable solid or liquid pharmaceutical active ingredient and/or
7 auxiliary agent.

1 11. (Original) Pharmaceutical composition according to
2 Claim 10 suitable for the reduction of the consequences of acute
3 ischemic or traumatic brain and spinal damage, especially the
4 various types of stroke or cerebral vasospasm, severe brain vessel
5 occlusion, neuronal loss and its functional consequences in the
6 case of head and spinal injuries caused by accidents.

1 12. (Original) Pharmaceutical composition according to
2 Claim 10 suitable for the treatment of neurodegenerative diseases.

1 13. (Original) Pharmaceutical composition according to
2 Claim 11 suitable for the treatment of motoneuron disease (ALS),
3 sclerosis multiplex or Creutzfeld-Jakob disease.

1 14. (Currently amended) Pharmaceutical composition
2 according to ~~any of Claim 10-13~~ claim 1 comprising
3 (1R,2S,4R)-(+)-2-(2-dimethylaminoethoxy)-2-phenyl-1,7,7-trimethyl-bic
4 yclo[2.2.1]heptane of the Formula II or a pharmaceutically
5 acceptable acid addition salt as compound of the general Formula I.

1 15. (Original) Pharmaceutical composition according to
2 Claim 14 comprising (1R,2S,4R)-(-)-2-(2-dimethylaminoethoxy)-2-
3 phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane-fumarate as compound
4 of the general Formula I.

1 16. (Currently amended) Use of compounds of the general
2 Formula I as defined in claim 1 (wherein R¹, R² and R³ are as
3 stated in Claim 1) and pharmaceutically acceptable acid addition
4 salts thereof as neuroprotective pharmaceutical active ingredient.

1 17. (Original) Use according to Claim 16 for the
2 reduction of the consequences of acute ischemic or traumatic brain
3 and spinal damages, especially the various types of stroke or
4 cerebral vasospasm, severe brain vessel occlusion, neuronal loss
5 and its functional consequences in the case of head and spinal
6 injuries caused by accidents.

1 18. (Original) Use according to Claim 16 for the
2 treatment of chronical neurodegenerative diseases.

1 19. (Original) Use according to Claim 16 for the
2 treatment of motoneuron disease (ALS), sclerosis multiplex or
3 CreutzfeldJakob disease.

1 20. (Currently amended) Use of
2 (1R,2S,4R)-(-)-2-(2-dimethylaminethoxy)-2-phenyl-1,7,7-trimethyl-bi
3 cyclo[2.2.1]heptane of the Formula II as defined in claim 7 and
4 pharmaceutically acceptable acid addition salts thereof in the
5 treatment of neuroprotective disorders, for the reduction of the
6 consequences of acute ischemic or traumatic brain and spinal
7 damages, especially the various types of stroke or cerebral
8 vasospasm, severe brain vessel occlusion, neuronal loss and its
9 functional consequences in the case of head and spinal injuries
10 caused by accidents, for the treatment of chronic neurodegenerative
11 diseases or for the treatment of motoneuron disease (ALS),
12 sclerosis multiplex or CreutzfeldJakob disease indications
13 according to Claims 16-19.

1 21. (Currently amended) Use of
2 (1R,2S,4R)-(-)-2-(2-dimethylaminoethoxy)-2-phenyl-1,7,7-trimethyl-b
3 icyclo[2.2.1]heptane-fumarate in the treatment of neuroprotective
4 disorders, for the reduction of the consequences of acute ischemic
5 or traumatic brain and spinal damages, especially the various types
6 of stroke or cerebral vasospasm, severe brain vessel occlusion,
7 neuronal loss and its functional consequences in the case of head
8 and spinal injuries caused by accidents, for the treatment of
9 chronic neurodegenerative diseases or for the treatment of
10 motoneuron disease (ALS), sclerosis multiplex or CreutzfeldJakob
11 disease indications according to Claims 16-19.

1 22. (Currently amended) Neuroprotective method of
2 treatment which comprises administering to the patient in need of
3 such treatment a compound of the general Formula I or a
4 pharmaceutically acceptable acid addition salt thereof as defined
5 in claim 1, preferably preferably (1R,2S,4R)-(-)-2-
6 (2-dimethylaminoethoxy)-2-phenyl-1,7,7-trimethylbicyclo[2.2.1]hepta
7 ne of the Formula II or a pharmaceutically acceptable acid addition
8 salt thereof in a therapeutically therapeutically active amount.